Delays in tuberculosis diagnosis and treatment in India: A patient journey analysis from Mumbai and Patna during the COVID-19 Pandemic
4 affiliations
- 1Cardiac Services BC, Provincial Health Service Authority, British Columbia, Canada
- 2Research Institute of the McGill University Health Centre, Montréal, Quebec, Canada
- 3McGill International TB Centre, Montreal, Canada
- 4Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada
Abstract
Tuberculosis (TB) care for people with TB in India are often fragmented, undermining timely diagnosis and treatment. Understanding patient journeys is critical to strengthening TB care delivery and advancing elimination goals. We conducted a cross-sectional study of 400 people with TB diagnosed between 2020–2022 in two Indian cities: Mumbai (n = 200) and Patna (n = 200). Using structured interviews, we assessed care-seeking behavior, delays to diagnosis and treatment, the number and type of healthcare encounters, and out-of-pocket costs. Participants predominantly initiated care in the private sector (Mumbai 91%; Patna 85%), often at pharmacies or private clinics. Care journeys were fragmented, with multiple provider visits before diagnosis. The median total delay from symptom onset to treatment initiation was 35 days (IQR 13–81) in Patna and 26 days (IQR 12–59) in Mumbai. Provider delays contributed a median of ~19 days in both cities. Participants made a median of 3 pre-diagnosis healthcare visits, and 23% had ≥ 6 encounters. The financial burden was substantial particularly in Mumbai, where consultation and diagnostic costs were higher than in Patna. Longer delays and more encounters were associated with male sex, unemployment, larger household size, and care-seeking hesitancy during the study period. Patient journeys in urban India during the COVID-19 pandemic were prolonged and costly, with delays driven primarily by systemic fragmentation rather than patient hesitancy. The reliance on an under-regulated private sector led to multiple pre-diagnosis encounters (23% requiring more than 6) and significant out-of-pocket costs. Because no individual characteristic consistently predicted delay, these findings suggest that structural reforms including standardized diagnostic pathways and enhanced public-private integration are essential to build health system resilience and accelerate TB elimination.
Related
- Recorrido y barreras en el acceso a diagnóstico y tratamiento de la enfermedad de Chagas en Argentina: un mapa desde la experiencia de las personas The journey and barriers to accessing diagnosis and treatment for Chagas disease in Argentina: a patient journey map based on people’s experiences Percurso e barreiras no acesso ao diagnóstico e ao tratamento da doença de Chagas na Argentina: um panorama a partir de experiências pessoais
- Patient Journey and Treatment Patterns of Non-Muscle-Invasive Bladder Cancer in Mexico.
- Impact of the COVID-19 pandemic on diagnosis, treatment, and prognosis of cervical, endometrial, and ovarian cancers: A retrospective cohort study based on the SEER database.
- Effectiveness of psychosocial counselling on treatment adherence among patients with a new tuberculosis diagnosis in primary care: a study protocol for a cluster-randomised controlled trial
- Retrospective Analysis of Tuberculosis Treatment Duration and Outcomes Using Explainable Machine Learning on Malaysian Patient Data
BibTeX
@article{kafi2026delays,
title = {{Delays in tuberculosis diagnosis and treatment in India: A patient journey analysis from Mumbai and Patna during the COVID-19 Pandemic}},
author = {Mohammad Abdullah Heel Kafi and Poshan Thapa and Madhukar Pai and Charity Oga-Omenka},
journal = {PLOS Global Public Health},
year = {2026},
month = sep,
doi = {10.1371/journal.pgph.0007214},
url = {https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0007214},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Delays in tuberculosis diagnosis and treatment in India: A patient journey analysis from Mumbai and Patna during the COVID-19 Pandemic
AU - Mohammad Abdullah Heel Kafi
AU - Poshan Thapa
AU - Madhukar Pai
AU - Charity Oga-Omenka
PY - 2026
DA - 2026/09/16
JO - PLOS Global Public Health
DO - 10.1371/journal.pgph.0007214
UR - https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0007214
AB - Tuberculosis (TB) care for people with TB in India are often fragmented, undermining timely diagnosis and treatment. Understanding patient journeys is critical to strengthening TB care delivery and advancing elimination goals. We conducted a cross-sectional study of 400 people with TB diagnosed between 2020–2022 in two Indian cities: Mumbai (n = 200) and Patna (n = 200). Using structured interviews, we assessed care-seeking behavior, delays to diagnosis and treatment, the number and type of healthcare encounters, and out-of-pocket costs. Participants predominantly initiated care in the private sector (Mumbai 91%; Patna 85%), often at pharmacies or private clinics. Care journeys were fragmented, with multiple provider visits before diagnosis. The median total delay from symptom onset to treatment initiation was 35 days (IQR 13–81) in Patna and 26 days (IQR 12–59) in Mumbai. Provider delays contributed a median of ~19 days in both cities. Participants made a median of 3 pre-diagnosis healthcare visits, and 23% had ≥ 6 encounters. The financial burden was substantial particularly in Mumbai, where consultation and diagnostic costs were higher than in Patna. Longer delays and more encounters were associated with male sex, unemployment, larger household size, and care-seeking hesitancy during the study period. Patient journeys in urban India during the COVID-19 pandemic were prolonged and costly, with delays driven primarily by systemic fragmentation rather than patient hesitancy. The reliance on an under-regulated private sector led to multiple pre-diagnosis encounters (23% requiring more than 6) and significant out-of-pocket costs. Because no individual characteristic consistently predicted delay, these findings suggest that structural reforms including standardized diagnostic pathways and enhanced public-private integration are essential to build health system resilience and accelerate TB elimination.
SN - 2767-3375
ER -